Related references
Note: Only part of the references are listed.Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis
Yanli Zhuang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
K. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis
Philip J. Mease
CURRENT OPINION IN RHEUMATOLOGY (2015)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E. M. Griffiths et al.
LANCET (2015)
Clinical improvement in psoriasis with specific targeting of interleukin-23
Tamara Kopp et al.
NATURE (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Kenneth B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database
Kiyoshi Kubota et al.
BMJ OPEN (2015)
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
Howard Sofen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
A New Player on the Psoriasis Block: IL-17A-and IL-22-Producing Innate Lymphoid Cells
Nicole L. Ward et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Composition of Innate Lymphoid Cell Subsets in the Human Skin: Enrichment of NCR+ ILC3 in Lesional Skin and Blood of Psoriasis Patients
Marcel B. M. Teunissen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Characterization of Innate Lymphoid Cells in Human Skin and Blood Demonstrates Increase of NKp44+ILC3 in Psoriasis
Federica Villanova et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice
Stanislav Pantelyushin et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Yihua Cai et al.
IMMUNITY (2011)
Identification of a Novel Proinflammatory Human Skin-Homing Vγ9Vδ2 T Cell Subset with a Potential Role in Psoriasis
Ute Laggner et al.
JOURNAL OF IMMUNOLOGY (2011)
Cytokine Requirements for the Differentiation and Expansion of IL-17A-and IL-22-Producing Human Vγ2Vδ2 T Cells
Kristin J. Ness-Schwickerath et al.
JOURNAL OF IMMUNOLOGY (2010)
Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis
Nikhil Yawalkar et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2009)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage
Gretta L. Stritesky et al.
JOURNAL OF IMMUNOLOGY (2008)
Development, cytokine profile and function of human interleukin 17-producing helper T cells
Nicholas J. Wilson et al.
NATURE IMMUNOLOGY (2007)
Pathogenesis and therapy of psoriasis
Michelle A. Lowes et al.
NATURE (2007)
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17
S Aggarwal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Share Paper
